Closed-loop for People Living With Cystic Fibrosis Related Diabetes
This study investigates a new system called CamAPS FX, often called an 'artificial pancreas', for managing blood sugar in young people (aged 16 and over) and adults who have diabetes linked to cystic fibrosis. We want to see if this system is better than their usual insulin treatment combined with a Continuous Glucose Monitor (CGM). The study will look at how well blood sugar levels are controlled, how it affects lung function, body weight, and general quality of life. Safety is also very important. Participants will use one of the treatments for about 26 weeks, with full support available. This research aims to find better ways to help people with cystic fibrosis-related diabetes live healthier lives.
Auf einen Blick
Worum geht es in dieser Studie?
This research study is looking at a new way to help manage diabetes in young people and adults (aged 16 and over) who also have cystic fibrosis. This type of diabetes is called Cystic Fibrosis Related Diabetes (CFRD). The new approach is a special system named CamAPS FX, sometimes called a 'closed-loop' system or an 'artificial pancreas'. It's designed to automatically adjust insulin delivery based on blood sugar readings, making it easier to keep levels stable.
We want to compare how well this new CamAPS FX system works against the standard way people currently manage their CFRD. The usual method involves using insulin, often with the help of a Continuous Glucose Monitor (CGM), which constantly checks blood sugar levels. We're hoping to find out if the CamAPS FX system helps people keep their blood sugar within a healthy range more often, leading to better overall health and an improved daily life.
Over a period of around 26 weeks, participants will either use the CamAPS FX system or continue with their usual insulin and CGM. The study will carefully check how blood sugar levels change and also look at other important health aspects like lung function, body weight, and how people feel about their quality of life. Safety is a top priority, and the research team will provide training and support throughout the study to make sure everyone is safe and comfortable with the devices.
Wichtige Erkenntnisse
- Compares a new 'artificial pancreas' (CamAPS FX) to standard diabetes care.
- For young people and adults (16+) with cystic fibrosis-related diabetes.
- Aims to improve blood sugar control and quality of life.
- Study lasts for about 26 weeks with training and 24/7 support.
- Checks blood sugar, lung function, body weight, and wellbeing.
- Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.
Wer könnte berechtigt sein?
To join this study, you need to be at least 16 years old and have diabetes related to cystic fibrosis, for which you've been using insulin for at least three months. It's important that your current blood sugar control, specifically your 'time in target range', is less than 80% when using a CGM. Your lung function also needs to be at a certain level, specifically your FEV1 should be more than 30% of what's expected for someone your age and height.
You should be prepared to wear study devices like a glucose monitor, insulin pump, and smartphone all the time, and be willing to follow the study instructions carefully. If you've recently had an organ transplant or are on a waiting list, or if you've recently started a new cystic fibrosis medication (called a CFTR modulator) in the last month, you likely won't be able to take part.
Other reasons you might not be able to join include severe vision or hearing problems, a known allergy to insulin or plaster adhesives, serious skin conditions where the sensors would be placed, or if you are pregnant, breastfeeding, or planning to become pregnant in the next year. The study team will review all of these details with you to ensure it's safe and appropriate for you to participate.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 16 Jahre alt oder älter?
- Do you have cystic fibrosis-related diabetes and use insulin?
- Have you been using insulin for at least 3 months?
- Can you wear devices like a glucose monitor and phone all the time?
- Is your current lung function (FEV1) above 30% of what's expected for you?
Was beinhaltet die Teilnahme?
If you join this study, you'll first have a 'run-in' period to get everything set up. After that, you'll be randomly assigned to one of two groups for about 26 weeks (roughly six months). One group will use the new CamAPS FX system, which is a 'closed-loop' system that helps manage insulin automatically. The other group will continue with their usual insulin treatment, along with a Continuous Glucose Monitor (CGM) to track blood sugar.
Everyone will receive proper training on how to use their assigned devices safely. Throughout the 26-week period, you'll have access to the study team for support, including 24/7 telephone help if you need it. We'll regularly check your blood sugar levels using the CGM, and also look at other health markers like lung function (using a breathing test), your weight, and your HbA1c (a measure of average blood sugar). You'll also be asked to complete questionnaires about your quality of life and your experiences with managing diabetes. There will be regular visits to the study clinic during these 26 weeks, but the exact number will be explained by the study team.
Potenzielle Risiken und Vorteile
Standorte (14)
- Belfast City HospitalVerifizierte PostleitzahlBelfast, Vereinigtes Königreich
- University Hospitals Bristol NHS Foundation TrustVerifizierte PostleitzahlBristol, Vereinigtes Königreich
- Addenbrooke's KrankenhausVerifizierte PostleitzahlCambridge, Vereinigtes Königreich
- Royal Papworth HospitalVerifizierte PostleitzahlCambridge, Vereinigtes Königreich
- All Wales Adult CF CentreVerifizierte PostleitzahlCardiff, Vereinigtes Königreich
- Queen Elizabeth University HospitalVerifizierte PostleitzahlGlasgow, Vereinigtes Königreich
- Glenfield HospitalVerifizierte PostleitzahlLeicester, Vereinigtes Königreich
- Kings College KrankenhausVerifizierte PostleitzahlLondon, Vereinigtes Königreich
- Royal Brompton HospitalVerifizierte PostleitzahlLondon, Vereinigtes Königreich
- St Bartholomew's HospitalVerifizierte PostleitzahlLondon, Vereinigtes Königreich
- Wythenshawe Hospital, Manchester University NHS Foundation TrustVerifizierte PostleitzahlManchester, Vereinigtes Königreich
- Oxford University Hospitals NHS Foundation TrustVerifizierte PostleitzahlOxford, Vereinigtes Königreich
Häufige Fragen
What is CamAPS FX?
It's an 'artificial pancreas' system that helps manage blood sugar automatically by adjusting insulin delivery based on your glucose readings.
Wer kann an dieser Studie teilnehmen?
Young people (16+) and adults with cystic fibrosis-related diabetes who use insulin and meet specific health criteria, like certain lung function levels.
Wie lange dauert die Studie?
The main part of the study where you use one of the treatments will last about 26 weeks, which is roughly six months.
Will I get help using the devices?
Yes, you'll receive full training on how to use the devices safely, and there's 24/7 telephone support available from the study team.
Was passiert, wenn ich nicht mehr teilnehmen möchte?
You are free to leave the study at any time, for any reason, and it won't affect your future medical care.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.